The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice.
Methods:
Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth factor (anti-VEGF) therapy. The primary outcome compared mean change in VA between switch and Month 12 to test the noninferiority of switching from ranibizumab to aflibercept vs aflibercept to ranibizumab. Comparing the number of injection/noninjection visits was the key secondary objective.
Results:
A total of 269 eyes switching from ranibizumab to aflibercept and 83 switching from aflibercept to ranibizumab were included. The mean change in VA (letters) after 12 months in eyes switched from ranibizumab to aflibercept, and from aflibercept to ranibizumab, was –1.56 and 0.21, respectively (P = .65). The adjusted difference (95% confidence interval) of mean change at Month 12 was 1.29 (–2.97 to 5.55; P = .55), confirming the noninferiority of ranibizumab. The mean (±SD) number of injections during follow-up was 8.67 (±2.63) for eyes switching from aflibercept to ranibizumab and 7.79 (±2.77) for ranibizumab to aflibercept (P = .01).
Conclusions:
Switching between anti-VEGFs is not associated with clinically relevant differences in VA at 12 months in routine clinical practice.
FerreiraASagkriotisAOlsonMLuJMakinCMilnesF. Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PloS One. 2015;10(7):e0133968. doi:10.1371/journal.pone.0133968
2.
QuillenDA. Common causes of vision loss in elderly patients. Am Fam Physician. 1999;60(1):99–108.
3.
BrownDMMichelsMKaiserPK. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65.e5. doi:10.1016/j.ophtha.2008.10.018
4.
RosenfeldPJBrownDMHeierJS. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
HoACBusbeeBGRegilloCD. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192. doi:10.1016/j.ophtha.2014.05.009
HolekampNMLiuYYehWS. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157(4):825–833.e1. doi:10.1016/j.ajo.2013.12.018
10.
JohnstonSSWilsonKHuangASmithDVarkerHTurpcuA. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther. 2013;30(12):1111–1127. doi:10.1007/s12325-013-0078-4
DugelPUGrinerRMilnesF. Clinical effectiveness of ranibizumab and aflibercept for neovascular AMD: a retrospective cohort study using electronic medical records from the US. Poster presented at: European School for Advanced Studies in Ophthalmology Retina Academy; October 22-24, 2015; Barcelona, Spain.
13.
CATT Research Group, MartinDFMaguireMG. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673
14.
BinderS. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?Br J Ophthalmol. 2012;96(1):1–2. doi:10.1136/bjophthalmol-2011-301236
15.
RicciFParravanoMRegineF. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye (Lond). 2016;30(8):1077–1083. doi:10.1038/eye.2016.95
16.
GrewalDSGillMKSarezkyDLyonATMirzaRG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28(7):895–899. doi:10.1038/eye.2014.101
17.
HoVYYehSOlsenTW. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23–28.e2. doi:10.1016/j.ajo.2013.02.009
18.
KumarNMarsigliaMMrejenS. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605–1612. doi:10.1097/IAE.0b013e31828e8551
19.
LazzeriSRipandelliGSartiniMS. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18(4):397–432. doi:10.1007/s10456-015-9483-4
20.
PapadopoulosNMartinJRuanQ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185. doi:10.1007/s10456-011-9249-6
21.
YonekawaYAndreoliCMillerJB. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29–35.e2. doi:10.1016/j.ajo.2013.03.030
22.
BarthelmesDCampainANguyenP. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016;100(12):1640–1645. doi:10.1136/bjophthalmol-2015-308090
23.
AghdamKAPielenAFrammeCJunkerB. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol. 2016;26(5):473–478. doi:10.5301/ejo.5000757
24.
ChangAABroadheadGKHongT. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res. 2015;55(2):84–90. doi:10.1159/000440886
25.
SinghRPSrivastavaSKEhlersJP. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clin Ophthalmol. 2015;9:1759–1766. doi:10.2147/OPTH.S87043
26.
MantelIGianniouCDiraniA. Conversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatment. Retina. 2016;36(1):53–58. doi:10.1097/IAE.0000000000000664
27.
SleanGRHemaratKKhuranaRNStewartJM. Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series. Int J Retina Vitreous. 2016;2:2. doi:10.1186/s40942-016-0028-9
28.
ChakravarthyUBezlyakVSagkriotisA. Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: real world evidence. Opthalmol Retina. 2019;3(1):8–15.e1. doi:10.1016/j.oret.2018.09.001
29.
FerrisFLIIIMaguireMGGlassmanARYingGSMartinDF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol. 2017;135(2):145–149. doi:10.1001/jamaophthalmol.2016.4820
